CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Pemetrexed Alimta for Advanced Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) - Details

Project Number PC0027-000
Brand Name Alimta
Generic Name Pemetrexed
Strength 100mg/vial and 500mg/vial
Tumour Type Lung
Indication Advanced Non-Squamous Non Small Cell Lung Cancer
Funding Request For maintenance following first-line pemetrexed and cisplatin for advanced or metastatic Non Squamous -Non Small Cell Lung Cancer (NS-NSCLC)
Review Status Complete
Pre Noc Submission No
NOC Date May 9, 2013
Manufacturer Eli Lilly Canada
Sponsor Eli Lilly Canada
Submission Date May 31, 2013
Submission Deemed Complete June 13, 2013
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ June 14, 2013
Check-point meeting August 30, 2013
pERC Meeting October 17, 2013
Initial Recommendation Issued October 31, 2013
Feedback Deadline ‡ November 15, 2013
Final Recommendation Issued November 19, 2013
Notification to Implement Issued December 4, 2013
Therapeutic Area Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.